🇺🇸 FDA
Pipeline program

Hyperpolarized Xe129

Pro00113235

Phase 2 small_molecule terminated

Quick answer

Hyperpolarized Xe129 for Pulmonary Artery Hypertension is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Pulmonary Artery Hypertension
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials